Developing Novel Drug Candidates

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Our goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

We are listed on the AIM market of the London Stock Exchange (symbol ‘SUMM’) and the NASDAQ Global Market (symbol ‘SMMT’).  Further information is available in our dedicated Investor Relations section.

Calendar

Scrip Awards 2016

Summit Therapeutics win
‘Clinical Advance of the Year’
for CoDIFy trial of ridinilazole
at the 2016 Scrip Awards:

 

web_scripawards

Stocks

Share Price

LSE: SUMM
188.65p -1.35
at 12:16am GMT 21 Feb 2017

NASDAQ: SMMT
$11.64 -0.05
at 08:00pm ET 17 Feb 2017